Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.53 |
| ▸ | RXRB | P28702 | 10/20 | 0.53 |
| ▸ | RXRG | P48443 | 9/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179352 | 0.89 | RXRA (0.43) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL22235630 | 0.85 | RXRA (0.40) | RXRARXRBRXRGKDM4EHDAC8 | |
| SCHEMBL22235371 | 0.85 | ALOX15 (0.42) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL5180005 | 0.84 | RXRA (0.39) | RXRARXRBRXRGHDAC8MAPT | |
| SCHEMBL5179522 | 0.83 | RXRA (0.58) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL22235297 | 0.83 | RXRA (0.57) | RXRARXRBRXRGPPARG | |
| SCHEMBL5179646 | 0.82 | KDM4E (0.54) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL22235352 | 0.78 | RXRA (0.55) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL22235910 | 0.78 | ALDH1A1 (0.45) | RXRARXRBRXRGALOX15HSD17B10 | |
| SCHEMBL22235324 | 0.76 | HCAR3 (0.58) | RXRARXRBRXRGPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089540-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2022-03-24 | — | — | US | disclosed |
| EP-3911309-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | Board Of Trustees Of Michigan State University (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150668-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-1180520-B1 | PYRIMIDINE CARBOXYLIC ACID DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-6869959-B1 | Heterocyclic carboxylic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2005-03-22 | — | — | US | disclosed |
| EP-1180520-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089540-A1 | COMPOSITIONS AND METHODS FOR IMMUNE MODULATION AND TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | RXRA 7/4885RXRB 6/4885RXRG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.